Amyloidosis medical therapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Amyloidosis}}
{{Amyloidosis}}
{{CMG}}; {{AE}}
{{CMG}} {{shyam}}; {{AE}}
 
{{PleaseHelp}}


==Overview==
==Overview==
There is no treatment for primary amyloidosis. Since the disease is typically discovered at an advanced stage, the initial treatment is aimed at preventing further organ damage, and correcting the effects of [[organ failure]].
There are few available treatments for primary amyloidosis. Since the disease is typically discovered at an advanced stage, the initial treatment is aimed at preventing further organ damage and correcting the effects of [[organ failure]].


==Medical Therapy==
==Medical Therapy==
Line 15: Line 13:
**[[Heart failure]] is treated using [[diuretics]].
**[[Heart failure]] is treated using [[diuretics]].
**Gastrointestinal and nerve involvement are treated symptomatically.
**Gastrointestinal and nerve involvement are treated symptomatically.
The most commonly used regimen is CyBorD, which consists of cyclophosphamide, bortezomib, and dexamethasone.
{|
| valign="top" |
|+
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Therapy}}
! style="background: #4479BA; width: 400px;" | {{fontcolor|#FFF|Mechanism of Action}}
! style="background: #4479BA; width: 400px;" | {{fontcolor|#FFF|Dosing}}
! style="background: #4479BA; width: 400px;" | {{fontcolor|#FFF|Adverse Effects}}
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |
Bortezomib
| style="padding: 5px 5px; background: #F5F5F5;" |
*Reversibly inhibits the 26S proteasome, preventing recycling of proteins and inducing cell cycle arrest and apoptosis
| style="padding: 5px 5px; background: #F5F5F5;" |
*Cycles 1-4: 1.3mg/m2 IV/SC on days 1, 4, 8, 11, 22, 25, 29, 32
*Cycles 5-9: 1.3mg/m2 IV/SC on days 1, 8, 22, 29
| style="padding: 5px 5px; background: #F5F5F5;" |
Peripheral neuropathy, VZV reactivation, hepatic impairment, asthenia, diarrhea, nausea, constipation, arthralgia, edema, dizziness
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |
Dexamethasone
| style="padding: 5px 5px; background: #F5F5F5;" |
*Suppresses polymorphonuclear leukocytes
*Inhibits prostaglandins and proinflammatory cytokines
*Suppresses lymphocyte proliferation
| style="padding: 5px 5px; background: #F5F5F5;" |
*40mg PO weekly
| style="padding: 5px 5px; background: #F5F5F5;" |
Infections, immunosuppression, bone loss, cataract formation, glaucoma, muscular atrophy
|-
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |
Melphalan
| style="padding: 5px 5px; background: #F5F5F5;" |
*Inhibits DNA and RNA synthesis
*Crosslinks DNA and causes DNA replication failure
| style="padding: 5px 5px; background: #F5F5F5;" |
*6mg PO daily for 2-3 weeks, OR
*10mg PO daily for 7-10 days, OR
*0.15mg/kg daily PO for 7 days, THEN
*1-3mg or 0.05mg/kg PO daily after counts recover
| style="padding: 5px 5px; background: #F5F5F5;" |
Myelosuppression, nausea, vomiting, pulmonary fibrosis, stomatitis
|-
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |
Cyclophosphamide
| style="padding: 5px 5px; background: #F5F5F5;" |
*Alkylating agent
*Crosslinks DNA and causes DNA replication failure
| style="padding: 5px 5px; background: #F5F5F5;" |
*40-50mg/kg weekly
| style="padding: 5px 5px; background: #F5F5F5;" |
Myelosuppression, nausea, vomiting, hemorrhagic cystitis, secondary malignancies
|-
|}
Treatment options with limited success include [[melphalan]], [[prednisone]], and [[colchicine]].
Treatment options with limited success include [[melphalan]], [[prednisone]], and [[colchicine]].



Revision as of 19:36, 2 January 2019

Amyloidosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Primary amyloidosis
Secondary amyloidosis
Familial amyloidosis
Wild-type (senile) amyloidosis
Cardiac amyloidosis
Beta-2 microglobulin related amyloidosis
Gelsolin related amyloidosis
Lysozyme amyloid related amyloidosis
Leucocyte cell-derived chemotaxin 2 related amyloidosis
Fibrinogen A alpha-chain associated amyloidosis

Pathophysiology

Causes

Differentiating Amyloidosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Amyloidosis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Amyloidosis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Amyloidosis medical therapy

CDC on Amyloidosis medical therapy

Amyloidosis medical therapy in the news

Blogs on Amyloidosis medical therapy

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Amyloidosis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2]; Associate Editor(s)-in-Chief:

Overview

There are few available treatments for primary amyloidosis. Since the disease is typically discovered at an advanced stage, the initial treatment is aimed at preventing further organ damage and correcting the effects of organ failure.

Medical Therapy

Some patients with primary amyloidosis respond to chemotherapy focused on the abnormal plasma cells. A stem cell transplant may be done, as in multiple myeloma.

The most commonly used regimen is CyBorD, which consists of cyclophosphamide, bortezomib, and dexamethasone.

Therapy Mechanism of Action Dosing Adverse Effects

Bortezomib

  • Reversibly inhibits the 26S proteasome, preventing recycling of proteins and inducing cell cycle arrest and apoptosis
  • Cycles 1-4: 1.3mg/m2 IV/SC on days 1, 4, 8, 11, 22, 25, 29, 32
  • Cycles 5-9: 1.3mg/m2 IV/SC on days 1, 8, 22, 29

Peripheral neuropathy, VZV reactivation, hepatic impairment, asthenia, diarrhea, nausea, constipation, arthralgia, edema, dizziness

Dexamethasone

  • Suppresses polymorphonuclear leukocytes
  • Inhibits prostaglandins and proinflammatory cytokines
  • Suppresses lymphocyte proliferation
  • 40mg PO weekly

Infections, immunosuppression, bone loss, cataract formation, glaucoma, muscular atrophy

Melphalan

  • Inhibits DNA and RNA synthesis
  • Crosslinks DNA and causes DNA replication failure
  • 6mg PO daily for 2-3 weeks, OR
  • 10mg PO daily for 7-10 days, OR
  • 0.15mg/kg daily PO for 7 days, THEN
  • 1-3mg or 0.05mg/kg PO daily after counts recover

Myelosuppression, nausea, vomiting, pulmonary fibrosis, stomatitis

Cyclophosphamide

  • Alkylating agent
  • Crosslinks DNA and causes DNA replication failure
  • 40-50mg/kg weekly

Myelosuppression, nausea, vomiting, hemorrhagic cystitis, secondary malignancies


Treatment options with limited success include melphalan, prednisone, and colchicine.

In secondary amyloidosis, aggressively treating the disease that is causing the excess amyloid protein can improve symptoms and/or slow the disease from getting worse. Complications such as heart failure, renal failure, and other problems can sometimes be treated, when needed.

References

Template:WH Template:WS